Cargando…

Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019

We compared rates of emergency department visits or hospitalizations among ambulatory coronavirus disease 2019 (COVID-19) patients treated with monoclonal antibody (mAb) therapy (n = 305) vs untreated patients (n = 6354). Treatment was associated with decreased encounters within 30 days (adjusted od...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anderson, Blake, Smith, Zirka, Edupuganti, Srilatha, Yan, Xiaobo, Masi, Christopher M, Wu, Henry M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279096/ https://www.ncbi.nlm.nih.gov/pubmed/34277887 http://dx.doi.org/10.1093/ofid/ofab315

Ejemplares similares

Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
por: Yetmar, Zachary A, et al.
Publicado: (2022)

Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency
por: Pulvirenti, Federica, et al.
Publicado: (2021)

Antigenic variation among bovine enteric coronaviruses (BECV) and bovine respiratory coronaviruses (BRCV) detected using monoclonal antibodies
por: Hasoksuz, M., et al.
Publicado: (2014)

Characterization of monoclonal antibodies to bovine enteric coronavirus and antigenic variability among Quebec isolates
por: Michaud, L., et al.
Publicado: (1993)

Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score
por: Johnson, Patrick W., et al.
Publicado: (2023)

Longitudinal Neutralizing and Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants Following Messenger RNA Coronavirus Disease 2019 Vaccination
por: Chen, Xuemin, et al.
Publicado: (2023)

Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study
por: Liao, Xuejiao, et al.
Publicado: (2022)

Rapid Emergence of Potentially Transmissible Severe Acute Respiratory Syndrome Coronavirus 2 With Resistance to Combination Monoclonal Antibody Therapy
por: Jacobs, Jana L, et al.
Publicado: (2023)

Fc-optimized monoclonal antibodies show superior efficacy
por: Flemming, Alexandra
Publicado: (2021)

Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity
por: Rössler, Annika, et al.
Publicado: (2022)

Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia in Patients Treated With Anti-CD20 Monoclonal Antibodies
por: Furie, Nadav, et al.
Publicado: (2023)

Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus
por: Sivapalasingam, Sumathi, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 Evolution and Escape From Combination Monoclonal Antibody Treatment in a Person With HIV
por: Khosravi, Dara, et al.
Publicado: (2023)

Clinical Outcomes of Acute Pancreatitis in Patients With Coronavirus Disease 2019
por: Dirweesh, Ahmed, et al.
Publicado: (2020)

Improvement of Anti-CD36 Antibody Detection via Monoclonal Antibody Immobilization of Platelet Antigens Assay by Using Selected Monoclonal Antibodies
por: Xu, Xiuzhang, et al.
Publicado: (2023)

Severe acute respiratory syndrome coronavirus-2 IgG antibody response to coronavirus disease 2019 vaccination in South Indian health-care professionals with and without coronavirus disease 2019 exposure
por: Jayashri, Ramamoorthy, et al.
Publicado: (2022)

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
por: Berry, Jody D, et al.
Publicado: (2004)

Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
por: Razonable, Raymund R, et al.
Publicado: (2022)

Natural infection by Zika virus but not DNA vaccination consistently elicits antibodies that compete with two potently neutralising monoclonal antibodies targeting distinct epitopes
por: Smith, Teresa C., et al.
Publicado: (2023)

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
por: Tian, Xiaolong, et al.
Publicado: (2020)

Prevalence, Risk Factors, and Outcomes of Hospitalized Patients With Coronavirus Disease 2019 Presenting as Acute Pancreatitis
por: Inamdar, Sumant, et al.
Publicado: (2020)

Croup during the Coronavirus Disease 2019 Omicron Variant Surge
por: Tunҫ, Emine M., et al.
Publicado: (2022)

Outcomes of Coronavirus Disease 2019 Drive-Through Screening at an Academic Military Medical Center
por: Lindholm, David A, et al.
Publicado: (2020)

Pericarditis Associated With Acute Zika Virus Infection in a Returning Traveler
por: Waggoner, Jesse J., et al.
Publicado: (2017)

Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019
por: Bainbridge, Emma D, et al.
Publicado: (2021)

The association between body mass index class and coronavirus disease 2019 outcomes
por: Al-Salameh, Abdallah, et al.
Publicado: (2020)

Neutralizing Monoclonal Antibodies for Coronavirus Disease 2019 (COVID-19) in Pregnancy: A Case Series
por: Richley, Michael, et al.
Publicado: (2022)

Monoclonal Antibody Therapy for COVID-19: A Public Health Perspective From Arkansas
por: Kothari, Atul, et al.
Publicado: (2022)

When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions
por: Bradbury, Andrew R. M., et al.
Publicado: (2018)

Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine( )
por: Maron, Jenny S, et al.
Publicado: (2022)

Special ambulatory gynecologic considerations in the era of coronavirus disease 2019 (COVID-19) and implications for future practice
por: Cohen, Megan A., et al.
Publicado: (2020)

Natriuretic Peptide Levels and Clinical Outcomes Among Patients Hospitalized With Coronavirus Disease 2019 Infection
por: Aslam, M. Imran, et al.
Publicado: (2021)

Trisomy 21 and Coronavirus Disease 2019 in Pediatric Patients
por: Newman, Alexander M., et al.
Publicado: (2021)

Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019
por: Leiva, Orly, et al.
Publicado: (2020)

Coronavirus Disease 2019 Outcomes Among Recipients of Anti‐CD20 Monoclonal Antibodies for Immune‐Mediated Diseases: A Comparative Cohort Study
por: Patel, Naomi J., et al.
Publicado: (2021)

Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City
por: Cowman, Kelsie, et al.
Publicado: (2021)

Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19
por: Webb, Brandon J, et al.
Publicado: (2021)

Association Between Genetic Predictors for C-Reactive Protein and Venous Thromboembolism With Severe Adverse Coronavirus Disease 2019 Outcomes
por: Guo, Boya, et al.
Publicado: (2021)

Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant
por: O’Horo, John C., et al.
Publicado: (2022)

Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment
por: Woltemate, Thomas J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bu58khofjti9r08hg5b790eia9